Antitumor drugs and immunomodulators

Combined with luteinizing hormone-releasing hormone (LHRH) analogues or surgical orchiectomy for the treatment of advanced prostate cancer.

It is used to treat patients with locally recurrent or metastatic, progressive and radioactive iodine refractory differentiated thyroid cancer; combined with Everolimus, it is used to treat patients with advanced renal cell carcinoma who have received targeted therapy of vascular endothelial growth factor in the past; combined with Pembrolizumab, it is used to treat patients with advanced endometrial cancer with non-microsatellite high instability or mismatch repair defect.

Used for frequent urination, urgent urination and urinary incontinence caused by overstimulation of bladder.

Indications: Solid malignant tumor

Indications: Ovarian cancer

Indications: Patients with advanced solid tumors

Indications: Patients with solid tumor

Indications: Patients with metastatic colorectal cancer

Indications: Prostate cancer, breast cancer

Indications: Solid tumor

Indications: Recurrent or metastatic solid tumors